Slide 1: Investor Presentation 2024-25
Investor Presentation 2024-25
Slide 2: Creating Sustained Shareholder Value
Creating Sustained Shareholder Value Strong & establish Diversified presence core business across market New product Robust balance sheet to development is growth support organic & driver- Focus on R&D inorganic moves Emphasis on Strong focus on productivity & efficient compliance & quality resource
Slide 3: FY'25 Key Highlights
FY’25 Key Highlights Healthy growth in Domestic own brand & Strong cash flows from 01 02 International business operating activities Domestic Oncology trade business 04 New launches driving a growing 03 share of overall business surpasses ₹100 Cr milestone COFEPRIS audit successfully cleared for 05
Slide 4: FY'25: Performance
OT @NBETA FY 25: Performance
Slide 5: Financial Performance (FY'25 Year-over-Year)
Financial Performance (FY’25 Year-over-Year) FY’22 FY’23 FY’24 FY’25 Growth (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) over FY’24 Healthy Growth in H1’25 Total revenue 183.84 227.11 295.71 362.36 23% EBITDA (ignoring 43.45 53.88 61.36 81.04 32% exceptional items) EBITDA (with 43.45 53.88 61.36 76.47 25% except
Slide 6: Financial Performance (FY'25 Year-over-Year)
Financial Performance (FY’25Year-over-Year) -------------------------------------- Current Ratio % Gross Margin 3.22 42.8% 41.5% 1.98 2.03 2.10 39.0% 38.7% FY'22 FY'23 FY'24 FY'25 FY'22 FY'23 FY'24 FY'25 ------------------------------------------------------------------------------------------------
Slide 7: Sales Performance (FY'25 Year-over-Year)
Sales Performance (FY’25 Year-over-Year) Revenue growth Growth has been driven by Domestic own Branded and International business 362.36 29% growth in 295.71 Domestic Own 73% growth in 227.11 Brand (including International 183.83 Cosmeceutical Business business) FY'22 FY'23 FY'24 FY'25
Slide 8: Domestic Own Brand Business
Domestic Own Brand Business The company continues to outperform the Indian Oncology market Domestic own brand Oncology Sustainable growth- Increase business crossed 100 Cr Oral therapy contribution (48%) milestone 102.97 82.19 68.39 Continuous growth 55.17 Increased contribution from with a 5-year C
Slide 9: International Business
International Business Revenue & growth Market wise business contribution 79.49 % Contribution 36 46.03 28 27.9 19 18 21.26 FY'22 FY'23 FY'24 FY'25 Africa APAC LATAM MENA
Slide 10: About Company
02 A Wals About Company
Slide 11: Fastest Growing Indian Oncology Company
Fastest Growing Indian Oncology Company Market Reach Manufacturing and R&D Capabilities Global footprint- Present in 46+ countries Domestic market - Prescence in 85% 3 Manufacturing facilities: 2 formulation & corporate & govt hospitals 1 API manufacturing facility Product pipeline Employees Strong
Slide 12: Domestic Own Brand: Oncology
Domestic Own Brand: Oncology 135 SKUs in our portfolio Leading Brands in Oncology
Slide 13: Offering Quality Affordable Healthcare Products
Offering Quality Affordable Healthcare Products Our coverage in different segments of Oncology - Present in Oncology & Cosmeceutical therapeutic areas - 135+ products in Oncology - Products available in more 85% of corporate & Govt hospitals
Slide 14: Our CDMO Partners
Our CDMO Partners ✓ Partnership with 50+ companies Trusted ✓ 20+ top pharma companies are associated with us since last 5 years Partners We value our CDMO partners Sustained growth Important clients
Slide 15: Future Road Map
O 3 A Wals Future Road Map
Slide 16: Future Roadmap
Future Roadmap 450+ Cr. 362 Cr. 296 Cr. FY’25 FY’26 227 Cr. FY’24 FY’23 FY’22 FY’21 The company plans to establish its presence and expand in Indian & international markets
Slide 17: Road Map
Road Map Manufacturing of API for Focus on Own brand sales Research & Development domestic & International in Domestic & International market market
Slide 18: Focus on own brand sales
Focus on own brand sales Increasing our presence in tier 2 & tier 3 cities Our products are cost effective due backward integration. It is helping us to get entry in more number of NDDS formulations are giving competitive edge to grow in Govt & corporate hospitals domestic market Strengthening our p
Slide 19: Making Inroads in Cosmeceutical Market
Making Inroads in Cosmeceutical Market Agreement with the European Focus on high end company for the First to cosmetologist with the launch products in Indian launch of fillers. Cosmeceutical market Reached to the average Increasing our covered market sales of 1 Cr sales /month with the launch of ne
Slide 20: Expanding in International Market
Expanding in International Market Global accreditations to expand the international business across the globe 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Eurasia ZAZIBONA DHA Nepal Tanzania INVIMA COFEPRIS (Audit clear) Uganda Nigeria Cambodia EUGMP (Triggered) Ethiopia WHO GMP ANVISA Kenya Sr
Slide 21: Expanding in International Market
Expanding in International Market Joint Venture with IMGSA For local manufacturing of Regulatory approvals Oncology products EAEU approval It will lead to geographical expansion in Russia, Kazakhstan, Kyrgyzstan, Belarus & Armenia ZAZIBONA approval It will lead to geographical expansion in Expansion
Slide 22: International Business
International Business Focus on product registrations International Market Robust pipeline ahead Existing registrations Pipeline Middle East & Middle East Africa & Africa LATAM 47 LATAM 237 South East Asia South East Asia 75 203 97 CIS: 12 216 CIS: 50 231 registrations as on date 600+ registrations
Slide 23: Focus on R&D
Focus on R&D R&D focused on NDDS/novel formulations & non infringing synthesis of off-patent products
Slide 24: Focus on R&D
Focus on R&D 5 new brands launched in FY’25: Glushield, Adloid, Karezus, Adpomide, Agorif 4 6 7 1 3
Slide 25: Most Active in NDDS Formulations
Most Active in NDDS Formulations With the help of our Research and Development
Slide 26: Focus on API Business
Focus on API Business Wide portfolio of API 70% API facility with a world-class related to Oncology drugs of API for formulations microbial lab with the latest manufactured in-house equipment API business provides competitive advantage Key Highlights Strategic business enabler for the manufacturing
Slide 27: Balance sheet
04 ANBETA Balance sheet
Slide 28: Balance Sheet
Balance Sheet FY’22 FY’23 FY’24 FY’25 (Rs Cr) (Rs Cr) (Rs Cr) (Rs Cr) Share capital 9.61 9.61 9.61 10.09 Reserves 82.73 113.27 147.5 187.00 Borrowing (Long 16.58 16.04 136.38 term & short term) 11.00 Other liabilities 48.93 59.5 85.98 102.75 Total liabilities 157.85 198.42 254.09 436.23 Fixed asset
Slide 29: Disclaimer
Disclaimer • This corporate presentation has been prepared by Beta Drugs Limited (the “Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. • This presentation should not be construed as legal, tax,
Slide 30: Thanks
Thanks Head office: SCO 184, Sector 5 Panchkula 134114 Haryana (India) Website: www.betadrugslimited.com Email: info@betadrugslimited.com